A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Interventions

DRUG

HRS-7172 Tablets

HRS-7172 tablets.

Trial Locations (1)

Fudan University Affiliated Cancer Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY